Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity
- PMID: 19497072
- PMCID: PMC2852585
- DOI: 10.1111/j.1399-3062.2009.00407.x
Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity
Abstract
Mycophenolate mofetil (MMF) is one of the most frequently used immunosuppressive drugs in solid organ transplant recipients. MMF is an inhibitor of inosine-5'-monophosphate, and is able to preferentially inhibit B-cell and T-cell function. The immunosuppressive abilities of MMF have made it one of the most successful anti-rejection drugs in transplant patients, but patients also appear to have increased susceptibility to infections, specifically cytomegalovirus and BK virus. Despite its association with an increased risk of infection, MMF has also exhibited antimicrobial activity against pathogens including hepatitis C, Pneumocystis jirovecii, and human immunodeficiency virus. A thorough understanding of the functions of MMF on the immune system and interaction with infectious pathogens could be helpful in implementing preventative strategies against opportunistic infections in transplant patients.
Similar articles
-
Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).Clin Transplant. 1996 Feb;10(1 Pt 2):77-84. Clin Transplant. 1996. PMID: 8680053 Review.
-
The use of mycophenolate mofetil in transplant recipients.Immunopharmacology. 2000 May;47(2-3):215-45. doi: 10.1016/s0162-3109(00)00190-9. Immunopharmacology. 2000. PMID: 10878291 Review.
-
Mechanisms of action of mycophenolate mofetil.Lupus. 2005;14 Suppl 1:s2-8. doi: 10.1191/0961203305lu2109oa. Lupus. 2005. PMID: 15803924 Review.
-
[Mycophenolate mofetil].Rev Med Brux. 1998 Jun;19(3):139-43. Rev Med Brux. 1998. PMID: 9697397 French.
-
Mycophenolate mofetil in cardiac transplantation.Curr Opin Cardiol. 1998 Mar;13(2):117-21. doi: 10.1097/00001573-199803000-00008. Curr Opin Cardiol. 1998. PMID: 9593551
Cited by
-
A retrospective analysis of dermatological lesions in kidney transplant patients.Indian J Med Res. 2013 Jun;137(6):1188-92. Indian J Med Res. 2013. PMID: 23852300 Free PMC article.
-
Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.J Allergy Clin Immunol. 2020 Sep;146(3):479-491.e5. doi: 10.1016/j.jaci.2020.07.016. J Allergy Clin Immunol. 2020. PMID: 32896308 Free PMC article. Review.
-
In-hospital post-transplant acute hepatitis A viral (HAV) infection in a liver transplant recipient who was HAV seropositive pre-transplant.Saudi J Gastroenterol. 2019 Jan-Feb;25(1):67-70. doi: 10.4103/sjg.SJG_230_18. Saudi J Gastroenterol. 2019. PMID: 30117491 Free PMC article.
-
Immunosuppressive Agents-Effects on the Cardiovascular System and Selected Metabolic Aspects: A Review.J Clin Med. 2023 Nov 5;12(21):6935. doi: 10.3390/jcm12216935. J Clin Med. 2023. PMID: 37959400 Free PMC article. Review.
-
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.J Transl Med. 2012 Jun 15;10:122. doi: 10.1186/1479-5876-10-122. J Transl Med. 2012. PMID: 22704060 Free PMC article.
References
-
- Allison AC, Eugui EM. Mycophenolate mofetil and its mechanism of action. Immunopharmacology. 2000;47:85–118. - PubMed
-
- Jorge S, Guerra J, Santana A, Mil-Homens C, Prata MM. Mycophenolate mofetil: ten years’ experience of a renal transplant unit. Transplant Proc. 2008;40:700–704. - PubMed
-
- OPTN/SRTR Annual Report. Immunosuppression use for maintenance by regimen prior to discharge, 1997–2006 Recipients with kidney transplants. 2007. [accessed September 9, 2008]. Available at http://www.ustransplant.org.
-
- Lu F, Tu Y, Peng X, et al. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus. 2008;17:622–629. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical